Bayer's Structural Crossroads: Debt, Legal Clarity, and a Widening Analyst Split
Published on 08/13/2026 at 10:31 | Redaktion boerse-global.de
The recent burst of optimism around Bayer's operational recovery has cooled noticeably, with the stock shedding roughly 2.5 percent over the past week after an initial post-earnings pop. Wednesday's session captured the mood perfectly: shares slipped 2.1 percent to EUR 48.14, even as two major banks delivered sharply divergent verdicts on the company's prospects.
Jefferies held firm with a "Hold" rating and a EUR 46 price target, while the DZ Bank raised its fair value from EUR 54 to EUR 60 and reaffirmed a "Buy" recommendation. The gap between those two numbers — a full 14 euros — underscores just how differently the Street is reading the same set of facts.
A Balance Sheet That Holds the Key
At the heart of the debate sits a structural question that has resurfaced with renewed urgency: whether Bayer should be broken apart. Analysts at Der Aktionär revived the idea on Wednesday of splitting the conglomerate into its three divisions — Crop Science, Pharma, and Consumer Health — but the feasibility of such a move hinges almost entirely on one factor: the company's net debt.
Bayer took a meaningful step in early July, securing an additional EUR 3.0 billion via ad-hoc announcement to improve its capital structure. That move signals that balance-sheet repair remains the top priority, and it also explains why a breakup is viewed more as a medium-term scenario than an immediate catalyst. Each standalone entity would need to absorb a portion of the debt load, and until that burden is meaningfully reduced, a three-way split looks difficult to execute.
Should investors sell immediately? Or is it worth buying Bayer?
The Bull Case: Momentum on Multiple Fronts
Optimists point to several encouraging developments. The return to profitability in the second quarter, if sustained, would expand the company's maneuvering room for a future structural move. There's also the legal front: Bayer's victory before the US Supreme Court in the Durnell case — a 7-2 ruling that federal law can preempt state-level failure-to-warn claims when the EPA has confirmed product safety — could make glyphosate-related legal risks more predictable over time. That, in turn, would strengthen the valuation case for a standalone Crop Science unit.
The company has also been investing for the long term in its agriculture business. An exclusive licensing agreement with French seed specialist RAGT aims to develop hybrid wheat, with a planned market launch in the early 2030s. The revenue potential is estimated at up to EUR 1 billion annually by the mid-2040s — a signal that Bayer is building a credible standalone growth story for its largest division.
The Bear Case: Legal Uncertainty Persists
The other side of the ledger remains stubbornly unresolved. The court hearing for final approval of the USD 7.25 billion glyphosate class-action settlement has been postponed again, with a new date expected for September 14. Every delay prolongs the uncertainty about when Bayer will achieve legal closure — and without that clarity, allocating liability risks across separate entities becomes nearly impossible.
The market's nervousness is quantifiable: annualized volatility stands at 26 percent, and while the stock still trades roughly 20 percent above its 200-day moving average, the RSI of 52.7 suggests neither overbought nor oversold conditions. The shares are consolidating after a steep run-up, with the company's market capitalization at EUR 48.36 billion.
A Side Show With Symbolic Weight
Adding to the list of open items, Bayer continues to review its options regarding the Bayer 04 football GmbH after the Bundeskartellamt's final assessment of the 50+1 rule. The matter isn't balance-sheet relevant, but it illustrates how many fronts the company is managing simultaneously.
What September Will Tell
The analyst divide — EUR 46 on the low end, EUR 60 on the high — is unlikely to narrow until the September 14 hearing provides clarity on the settlement. For now, the breakup debate remains more of a companion to the stock than a driver of it. But if the legal picture clears and deleveraging progresses faster than expected, that theoretical scenario could quickly gain substance and begin moving the share price in earnest.
Ad
Bayer Stock: New Analysis - 13 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
